Drug intelligence / Profile preview

18F-DASA-10

Development stage: Preclinical
Lead developer: Stanford University
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-DASA-10 is a fluorine-18 labeled small molecule radiopharmaceutical used as a positron emission tomography (PET) tracer for the molecular imaging of pyruvate kinase M2 (PKM2). PKM2 is an enzyme isoform predominantly expressed in proliferating cells and is a key regulator of the Warburg effect in cancer cells. 18F-DASA-10 was developed as an improved version of the earlier tracer 18F-DASA-23, offering higher affinity (AC50 of 65 nM), enhanced cellular uptake, and better retention. It is specifically designed to image brain malignancies like gliomas, benefiting from low background uptake in healthy brain tissue and high tumor-to-background contrast.

Targets

PKM2 (Pyruvate kinase M2 isoform)

Beyond the preview

Go deeper on 18F-DASA-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-DASA-10.

Explore the full profile